Evidence map›Paper›PMID 40563458›Full record

ReviewBiomolecules2025

Advancements in SELEX Technology for Aptamers and Emerging Applications in Therapeutics and Drug Delivery.

Liangjie Feng, Yu Sun, Wenshen Jia, Yang Yu, Chang Liu, Jing Yang, Yunxia Luan, Jin Chen, Fengchao Wang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Biomolecules, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Liangjie FengCollege of Sciences, Shanghai Institute of Technology, 100 Haiquan Road, Shanghai 201418, China.
Yu SunCollege of Sciences, Shanghai Institute of Technology, 100 Haiquan Road, Shanghai 201418, China.
Wenshen JiaInstitute of Quality Standard and Testing Technology of BAAFS, Beijing 100097, China.
Yang YuCollege of Sciences, Shanghai Institute of Technology, 100 Haiquan Road, Shanghai 201418, China.
Chang LiuCollege of Sciences, Shanghai Institute of Technology, 100 Haiquan Road, Shanghai 201418, China.
Jing YangCollege of Sciences, Shanghai Institute of Technology, 100 Haiquan Road, Shanghai 201418, China.
Yunxia LuanInstitute of Quality Standard and Testing Technology of BAAFS, Beijing 100097, China.
Jin ChenCollege of Sciences, Shanghai Institute of Technology, 100 Haiquan Road, Shanghai 201418, China.
Fengchao WangCollege of Sciences, Shanghai Institute of Technology, 100 Haiquan Road, Shanghai 201418, China.

Funding

Collaborative innovation project of Shanghai Institute of Technology No. XTCX2023-22Science and Technology Talent Development Fund for Young and Middle-aged Teachers of Shanghai Institute of Technology No. ZQ2022-6The project was sponsored by Shanghai Sailing Program, China No. 20YF1447600
6 · The paper itself

Abstract

Nucleic acid aptamers, selected through the Systematic Evolution of Ligands by Exponential Enrichment (SELEX), are short nucleic acid sequences that exhibit high affinity and specificity towards diverse targets. Over the past three decades, substantial advancements have been made in both the technology and applications of nucleic acid aptamers. This review provides an in-depth analysis of the historical development and defining characteristics of aptamers, highlighting recent technological innovations in SELEX, including Capillary Electrophoresis SELEX, Microfluidic SELEX, Cell-SELEX, and others. We explore the applications of aptamers in therapeutic and targeted drug delivery, emphasizing their advantages over traditional antibodies such as cost-effectiveness, ease of synthesis, and lower immunogenicity. Key challenges such as stability, specificity, and efficient delivery are discussed, with proposed strategies for improvement including advanced chemical modifications and integration with nanotechnology. By integrating advanced technologies, aptamers hold significant promise for enhancing precision medicine and personalized therapeutic interventions, offering new avenues for the treatment of complex diseases.

Indexed as

Aptamers, NucleotideDrug Delivery SystemsSELEX Aptamer TechniqueAnimalsHumansAptamers, NucleotideaptamerconjugatesnanotechnologySELEXtargeted drug deliverytherapeutics

Identifiers

PMID40563458
PMCPMC12190505

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.